Carracedo Sarah, Palmero Ana, Neil Marcie, Hasan-Granier Anisa, Saenz Carla, Reveiz Ludovic
Organización Panamericana de la Salud Washington, D.C. Estados Unidos de América Organización Panamericana de la Salud, Washington, D.C., Estados Unidos de América.
Rev Panam Salud Publica. 2021 Mar 8;45:e33. doi: 10.26633/RPSP.2021.33. eCollection 2021.
A considerable number of clinical trials is being conducted globally in response to the COVID-19 pandemic, including in low- and middle-income countries such as those in the Latin America and Caribbean region (LAC). Yet, an abundance of studies does not necessarily shorten the path to find safe and efficacious interventions for COVID-19. We analyze the trials for COVID-19 treatment and prevention that are registered from LAC countries in the International Clinical Trials Registry Platform, and identify a trend towards small repetitive non-rigorous studies that duplicate efforts and drain limited resources without producing meaningful conclusions on the safety and efficacy of the interventions being tested. We further assess the challenges to conducting scientifically sound and socially valuable research in the LAC region in order to inform recommendations to encourage clinical trials that are most likely to produce robust evidence during the pandemic.
为应对新冠疫情，全球正在进行大量临床试验，包括在拉丁美洲和加勒比地区（LAC）等低收入和中等收入国家。然而，大量的研究并不一定能缩短找到针对新冠病毒安全有效干预措施的路径。我们分析了在国际临床试验注册平台上注册的来自拉丁美洲和加勒比地区国家的新冠治疗和预防试验，发现存在一种趋势，即小型重复性非严格研究不断出现，这些研究重复劳动，耗尽有限资源，却未能就所测试干预措施的安全性和有效性得出有意义的结论。我们进一步评估了在拉丁美洲和加勒比地区开展科学合理且具有社会价值研究面临的挑战，以便提出建议，鼓励开展在疫情期间最有可能产生有力证据的临床试验。
